Showing 112 of 112on this page. Filters & sort apply to loaded results; URL updates for sharing.112 of 112 on this page
AFM13-mediated activation of NK cells. One arm of AFM13 binds to the ...
AFM13 / Affimed
Affimed - AFM13 - Science and Technology - Innate Cell ...
️ MD Anderson CC on their trial Affimed AFM13 with cord blood-derived ...
Affimed NV (NASDAQ:AFMD) Administers AFM13 Dose To The First Phase 1 ...
AFM13 - Crunchbase Company Profile & Funding
A phase 1b study of AFM13 in combination with pembrolizumab in patients ...
Gene structure of tetravalent bispecific AFM13 antibody domains. The ...
AFM13 Cross Fields Validations - YouTube
AFM13 Proves Active in Relapsed/Refractory PTCL, Especially AITL ...
Figure 1 from A phase 1b study of AFM13 in combination with ...
AFM13 Showcases 100% ORR in Relapsed/Refractory CD30+ Hodgkin Lymphoma ...
AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in ...
Association Franco-Marocaine du 13 - AFM13
13 Treatment with AFM13 Innate Cell Engagers in Hematologic Tumors ...
(PDF) 894 The bispecific innate cell engagers AFM13 (CD30/CD16A) and ...
Table 2 from A phase 1b study of AFM13 in combination with ...
Contact - AFM13 - fer, acier, inox, découpe, pliage, emboutissage ...
LOGO
癌症疫苗迎来新纪元？KRAS抑制剂再添生力军... | AACR
双抗选手势头越猛，CAR-T玩家压力越大-蓝鲸财经
X-MOL视点：免疫治疗领域现"四猛八大锤" Affimed股价一周内尽收失地- X-MOL资讯
客观缓解率达32.4%，Affimed公布自研药物AFM13|AFM13|细胞淋巴瘤|NK细胞|CD30|PTCL|药物|-健康界
优质的NK细胞是NK细胞疗法的基础，Affimed就此与Artiva展开合作-干细胞&免疫细胞&外泌体&再生医学领域垂直媒体细胞世界
BioNews | Affimed：公布最新AFM13临床数据报告，治疗复发/难治性CD3... 作者：林出 微信公众号：蹊之美股生物医药 ...
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine ...
CD30/CD16A双抗AFM13+脐血来源NK细胞治疗淋巴瘤疗效优异-印塔健康官网
志同道合NK：AFM13+Pembrolizumab/AFM13+AB101 - 知乎
(PDF) AFM13: A first-in-class tetravalent bispecific anti-CD30/CD16A ...
Transforming Immuno - Oncology Using Next - Generation Immune Cell ...
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive ...
Affimed双抗acimtamig与“现货型”NK细胞组合疗法临床结果优秀，针对霍奇金淋巴瘤
BioNews | Affimed：AFM13+脐血来源NK细胞预复合治疗初步数据良好，股... 作者：Kirkland Hwang 微信公众 ...
Affimed Reports on Corporate Progress and Provides Regulatory Update ...
NK疗法100%ORR缔造者Affimed：商业版图与最新进展梳理 2022年11月18日/医麦客新闻 eMedClub News/--近日 ...
Affimed präsentiert neue AFM13-Daten | GoingPublic.de
Affimed (AFMD) Shifts Attention To Risky Combination Therapy | Seeking ...
#afm13 #afm28 #afm24 #affimedproud #whywefightcancer | Affimed
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine ...
技术小站 | 双特异性抗体简介
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct ...
Affimed: Developing First - In - Class Immune Cell Engagers for ...
19 Treatment with AFM24 Innate Cell Engagers in Solid Tumors CD16A ...
Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better! (NASDAQ ...
아피메드 아티바 NK 병용 1·2상, 호지킨림프종 완전관해 77% | 한국경제
FDA Grants FTD to AFM13/AB-101 in Relapsed/Refractory Hodgkin Lymphoma
Affimed 100% ORR的NK疗法进入2期临床，开启肿瘤免疫治疗新篇章 2023年5月25日/医麦客新闻 eMedClub News ...
Blood：AFM13联合派姆单抗治疗复发性/难治性霍奇金淋巴瘤-MedSci.cn
AFM13临床进展 - 2021年04月 - 行业研究数据 - 小牛行研
Anti-FCGR3A(AFM13 without CD30 biosimilar) mAb
AFM13-NK细胞疗法带来突破性进展，维布妥昔单抗耐药患者的新选择 - MedFind
AFM13/NK Cell Combination Shows Encouraging Responses in R/R Lymphoma
Natural killer (NK) cells combined with a novel bispecific antibody ...
Anti-FCGR3A(AFM13_VH_2 without CD30 biosimilar) mAb-FCGR3A Biosimilar ...
7 Redirecting and activating immune cells Tetravalent, bispecific ...
蒋晨教授《AFM》发文：转胞吞作用介导的肿瘤深部穿透用于胰腺癌... - 生物通
아피메드, 아티바 NK세포+인게이저 “FDA 패스트트랙” - 바이오스펙테이터
CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT ...
Protein structure and antibody formation pathway of the tetravalent ...
Frontiers | Natural killer cell engagers for cancer immunotherapy
AFM13与NK细胞相结合客观缓解率高达97%,NK细胞疗法在哪些抗癌领域大放异彩_全球肿瘤医生网
Cord Blood-Derived NK Cell Therapy Shows Remarkable Efficacy in ...
Table 1 from A phase 1 study of the bispecific anti-CD30/CD16A antibody ...
Table 3 from A phase 1 study of the bispecific anti-CD30/CD16A antibody ...
Slide 1
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody ...
双抗选手势头越猛，CAR-T玩家压力越大 谁能成为挑战者？这曾是CAR-T技术的一大悬念。但如今，谜底或许快要浮出水面。众多双抗领域的实力选手 ...
通用NK细胞联合疗法2期临床ORR达100%，CR持续增加！ 2022年11月5日/医麦客新闻 eMedClub News/--近日，临床阶段 ...
Anti-FCGR3A(AFM13 without CD30 biosimilar) mAb-FCGR3A阳性参照抗体-适用于ELISA-缔码生物
